
Opinion|Videos|July 29, 2024
Approaches to Switching Between Antihistamines and Other Medications When Treating Patients with Chronic Spontaneous Urticaria
A panel of experts discuss switching between different antihistimines and other medications when treating CSU patients.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- A significant number of patients with CSU do not respond adequately to antihistamines. What is your approach to switching between (or adding on) antihistamines and when do you switch to another class of medications?
- How does antihistamine switching and treatment selection correlate with timing of disease episodes?
- If patients aren’t responding well to antihistamines, which therapies do you use next? When do you consider using biologics? What considerations do you take into account and what ultimately is driving that decision?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement


